What is the 13F Pro Quality Score for GMAB?

13F Pro ranks GENMAB A/S (GMAB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GMAB's current score at https://13fpro.ai/company/GMAB (free sign-up required for the full ranking).

Where does 13F Pro source GMAB data?

All GENMAB A/S fundamentals and ownership data come directly from SEC EDGAR. GENMAB A/S files with the SEC under CIK 1434265. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GMAB in?

GENMAB A/S (GMAB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GMAB research updated on 13F Pro?

GMAB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GENMAB A/S(GMAB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434265 GMAB stock profile & AI dashboard →

13F Pro Quality Score

77.9/100

Rank #59 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

93.5/100

Profitability

96.0/100

Balance Sheet

99.6/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

98.1/100

Revenue Scale

85.4/100

Dilution Risk

94.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why GMAB Scores 78/100

exact factor attribution · 2026-09-11

GMAB's composite is driven by revenue growth and profitability, held back by free cash flow and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.7 pts

94th pct

Profitability

+6.9 pts

96th pct

Scale

+5.3 pts

85th pct

Capital efficiency

+5.0 pts

100th pct

Institutional flow

+2.4 pts

98th pct

Earnings growth

+2.4 pts

98th pct

Shareholder dilution

+2.2 pts

95th pct

Earnings quality

-2.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

GMAB Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for GENMAB A/S (GMAB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMAB at 77.9/100 on a 32-signal composite quality model, placing it at rank #59 of 2,961 stocks — the top 5% of the AI-ranked universe. GMAB scores in the top quartile across balance sheet strength (99.6), institutional flow (98.1), profitability (96.0). Areas of concern include free cash flow (30.0) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), GENMAB A/S reports quarterly revenue of $3.7B, net income of $963.0M. Top institutional holders of GMAB by reported 13-F value include Paradigm Biocapital Advisors, Orbis Allan Gray Ltd, ALLIANCEBERNSTEIN L.P., based on the most recent SEC filings. GMAB trades on the Nasdaq exchange and files with the SEC under CIK 1434265. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GENMAB A/S directly from SEC EDGAR.

✦

Fun facts about GENMAB A/S

Quirks, history, and lore behind GMAB — the kind of stuff that makes a stock memorable.

1
The Basics
A Danish biotechnology company · mid-cap · listed on Nasdaq · focused entirely on developing antibody-based cancer therapies.
2
The Numbers
Revenues are driven heavily by royalties and milestone payments from partners rather than direct sales — a lean model that can swing from hundreds of millions to over a billion in a good year.
3
The History
Founded in 1999 in Denmark, the company was built from the ground up around a single obsession: engineering fully human monoclonal antibodies that could outperform older therapies.
4
The Secret
It rarely goes it alone — its business model leans heavily on co-development partnerships with larger pharma giants, letting blockbuster drugs carry its name without carrying all the risk.
5
The Lore
Its antibody daratumumab, co-developed with Johnson & Johnson, became one of the best-selling multiple myeloma drugs in the world — a rare Danish export that reshaped blood cancer treatment.
6
The Giveaway
This Copenhagen-born antibody pioneer gave the world Darzalex and is now chasing the next generation of bispecific antibodies — all without ever building a traditional sales force.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving GMAB's Business? Latest 20-F Breakdown

✓ 4/4 datapoints verified

AI-extracted from GENMAB A/S's 20-F filed 2026-02-17 — FY2025 (year ended December 31, 2025). Every figure is machine-verified against the filing text on SEC EDGAR.

Genmab reported 66% of 2025 revenue from DARZALEX royalties as patent expiration looms in 2029, while advancing commercial launches of proprietary products EPKINLY and Tivdak.

Biggest Revenue Drivers

Royalties from partnered productsApproximately 66% of total revenue

Primarily DARZALEX royalties from J&J, which accounted for 66% of 2025 revenue; patent rights expire in 2029 in US, 2031 in Europe, beginning in 2030 in Japan

Product sales from proprietary and co-developed productsIncluded in remaining revenue

Includes net sales of EPKINLY (epcoritamab) co-developed with AbbVie and Tivdak (tisotumab vedotin) co-developed with Pfizer

Biggest Revenue Drivers

Total revenue: Not disclosed in this excerpt

Royalties from partnered productsApproximately 66% of total revenue

Primarily DARZALEX royalties from J&J, which accounted for 66% of 2025 revenue; patent rights expire in 2029 in US, 2031 in Europe, beginning in 2030 in Japan

Product sales from proprietary and co-developed productsIncluded in remaining revenue

Includes net sales of EPKINLY (epcoritamab) co-developed with AbbVie and Tivdak (tisotumab vedotin) co-developed with Pfizer

Watch Items from the Filing

DARZALEX royalties represent 66% of revenue; US patent protection expires 2029, triggering anticipated material decline in royalties upon expiration and biosimilar competition.
Substantial indebtedness incurred for Merus acquisition; restrictive debt covenants limit operational flexibility and require dedication of cash flow to debt service.
CMO for Rina-S manufacturing located in China; BIOSECURE Act enacted December 2025 could restrict use of Chinese biotechnology companies, risking supply disruption and commercialization delay.
Petosemtamab Phase III trials (LiGeR-HN1, LiGeR-HN2) expected to readout in 2026; BTD designations indicate strong development pathway but no assurance of regulatory approval.
Four lawsuits filed by Chugai in Japan (2024–2025) challenging EPKINLY patent validity; Genmab and AbbVie defend vigorously but outcome uncertain.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 20-F on SEC EDGAR →Share on X

Revenue

FY 2025

$3.7B

Net Income

FY 2025

$963.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+19.2% YoY

$3.72BFY 2025

FY22 $14.51BFY23 $2.39BFY24 $3.12BFY25 $3.72B

Total Assets

+100.7% YoY

$12.87BFY 2025

FY22 $30.12BFY23 $5.23BFY24 $6.41BFY25 $12.87B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.72B +19.2%	$3.12B +30.6%	$2.39B -83.5%	$14.51B +72.3%	$8.42B -16.8%	$10.11B
Total Assets	$12.87B +100.7%	$6.41B +22.6%	$5.23B -82.6%	$30.12B +22.7%	$24.54B +16.1%	$21.14B

Get alerted when GMAB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GENMAB A/S including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GMAB

Paradigm Biocapital Advisors LP
$360.8M13,133,131 sh
Orbis Allan Gray Ltd
$312.3M11,368,161 sh
ALLIANCEBERNSTEIN L.P.
$231.9M8,644,877 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$188.6M6,865,000 sh
Deep Track Capital, LP
$155.2M5,650,000 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$136.7M4,975,324 sh
BlackRock, Inc.
$128.3M4,671,252 sh
Sofinnova Ventures Inc
$111.1M4,045,215 sh
RENAISSANCE TECHNOLOGIES LLC
$96.6M3,517,850 sh
TWO SIGMA INVESTMENTS, LP
$96.3M3,506,843 sh

Fund	Value	Shares
Paradigm Biocapital Advisors LP	$360.8M	13,133,131
Orbis Allan Gray Ltd	$312.3M	11,368,161
ALLIANCEBERNSTEIN L.P.	$231.9M	8,644,877
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$188.6M	6,865,000
Deep Track Capital, LP	$155.2M	5,650,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$136.7M	4,975,324
BlackRock, Inc.	$128.3M	4,671,252
Sofinnova Ventures Inc	$111.1M	4,045,215
RENAISSANCE TECHNOLOGIES LLC	$96.6M	3,517,850
TWO SIGMA INVESTMENTS, LP	$96.3M	3,506,843

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GMAB on your watchlist

Track score changes the day GENMAB A/S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GMAB a good stock to buy?

13F Pro's AI-powered analysis of GENMAB A/S (GMAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GMAB are available on the GMAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GMAB is classified as a large company.

Which hedge funds own GMAB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GMAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GENMAB A/S's investment landscape.